References
- Olsen E, Vonderheid E, Pimpinelli N, . Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007;110:1713–1722.
- Willemze R, Jaffe ES, Burg G, . WHO-EORTC classification for cutaneous lymphomas. Blood 2005;105:3768–3785.
- Bradford PT, Devesa SS, Anderson WF, . Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood 2009;113:5064–5073.
- Foss F. Overview of cutaneous T-cell lymphoma: prognostic factors and novel therapeutic approaches. Leuk Lymphoma 2003; 44(Suppl. 3):S55–S61.
- Criscione VD, Weinstock MA. Incidence of cutaneous T-cell lymphoma in the United States,1973-2002. Arch Dermatol 2007;143:854–859.
- Hwang ST, Janik JE, Jaffe ES, . Mycosis fungoides and Sezary syndrome. Lancet 2008;371:945–957.
- Pichardo DA, Querfeld C, Guitart J, . Cutaneous T-cell lymphoma: a paradigm for biological therapies. Leuk Lymphoma 2004;45:1755–1765.
- Vidulich KA, Talpur R, Bassett RL, . Overall survival in erythrodermic cutaneous T-cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T-cell lymphoma. Int J Dermatol 2009;48:243–252.
- Bernengo MG, Novelli M, Quaglino P, . The relevance of the CD4+ CD26- subset in the identification of circulatin Sezary cells. Br J Dermatol 2001;144:125–135.
- Washington LT, Huh YO, Powers LC, . A stable aberrant immunophenotype characterizes nearly all cases of cutaneous T-cell lymphoma in blood and can be used to monitor response to therapy. BMC Clin Pathol 2002;2:5.
- Nichols J, Foss F, Kuzel TM, . Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies. Eur J Cancer 1997;33(Suppl. 1):S34–S36.
- Bacha P, Williams DP, Waters C, . Interleukin 2 receptor-targeted cytotoxicity. Interleukin 2 receptor-mediated action of a diphtheria toxin-related interleukin 2 fusion protein. J Exp Med 1988;167:612–622.
- Waters CA, Schimke PA, Snider CE, . Interleukin 2 receptor-targeted cytotoxicity. Receptor binding requirements for entry of a diphtheria toxin-related interleukin 2 fusion protein into cells. Eur J Immunol 1990;20:785–791.
- Williams DP, Snider CE, Strom TB, . Structure/function analysis of interleukin-2-toxin (DAB486-IL-2). Fragment B sequences required for the delivery of fragment A to the cytosol of target cells. J Biol Chem 1990;265:11885–11889.
- Olsen E, Duvic M, Frankel A, . Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001;19:376–388.
- Prince HM, Duvic M, Martin A, . Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. J Clin Oncol 2010;28:1870–1877.
- LeMaistre CF, Meneghetti C, Rosenblum M, . Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hematologic malignancies expressing the IL-2 receptor. Blood 1992; 79:2547–2554.
- LeMaistre CF, Saleh MN, Kuzel TM, . Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2. Blood 1998;91:399–405.